UNSPSC 51151639: Ethybenztropin or ethybenztropine or tropethydrylin

This classification denotes an anticholinergic agent with the molecular formula C22H27NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G1X2X9N95N, chemically known as 8-azabicyclo(3.2.1)octane, 3-(diphenylmethoxy)-8-ethyl-, endo- but generally known as ethybenztropine, which bears US NIH Compound Identifier 71637. European Medicines Agency schedules Etybenzatropine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07348MIG.

The term ETYBENZATROPINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). World Health Organization schedules ethybenztropine in its Anatomical Therapeutic Chemical (ATC) Classification. SMILES: CCN1C2CCC1CC(C2)OC(C3=CC=CC=C3)C4=CC=CC=C4.

UNSPSC 51151639 Ethybenztropin or ethybenztropine or tropethydrylin is a Commodity code that shows minimal recent state and local procurement activity aligned with its nominal pharmaceutical scope. The single recent opportunity in the block—Seminole County, Florida's IFB for naloxone and drug deactivation systems—is unrelated to the code's chemical compound name and does not reflect actual purchasing under this code. The mismatch suggests either miscoding at the issuing body or that this Commodity sits outside the mainstream state and local procurement market.

The Seminole County IFB (IFB60459723LAS, due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, and carried a two-year initial term with one-year renewal option. No other recent opportunities appear in the record, and no geographic spread across multiple states or issuing-body pattern emerges to characterize the code's current market. Bidders were required to submit unit pricing electronically, maintain workers' compensation and general liability insurance, comply with E-Verify and drug-free workplace requirements, and accept a three-month probationary termination window. The procurement noted potential FEMA funding and associated federal compliance obligations but did not specify set-aside or disadvantaged-enterprise restrictions.